Watch and chat LIVE on Youtube, Rumble, Rokfin, Twitter and Instagram Tuesdays and Thursdays at 2:00PM PST/ 5:00PM EST!
Support:
True Hemp Science
PROMO CODE: MONICA
First 100 customers to spend $80 or more get a free sample bottle of Hypnautica, an excellent end of the day relaxation tool and may inspire a lifted sense during your evening routines.
Become a PREMIUM SUBSCRIBER on Apple Podcasts for AD FREE episodes! all for the cost of one newspaper a month– i read the news so you dont have to!
Find, Follow, Subscribe & Rate on your favorite podcasting platform AND for video and social & more…
Rokfin: https://rokfin.com/monicaperez
Rumble: https://rumble.com/user/monicaperezshow
YouTube: https://www.youtube.com/c/MonicaPerez
Twitter/X: @monicaperezshow
Instagram: @monicaperezshow
Show Notes:
Cancer Care: The Role of Repurposed Drugs and Metabolic Interventions in Treating Cancer by Paul E Marik
Dr Kathleen Ruddy on After Hours Podcast
https://podcasts.apple.com/us/podcast/after-hours-with-dr-sigoloff/id1601073627?i=1000647804124
https://linkpop.com/lifehealthcart
Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054244/
The main findings show that 19% of the participants diagnosed with cancer take medicines based on ivermectin as alternative therapy to the cancer control and treatment without leaving treatment such as chemotherapy, radiotherapy, or immunotherapy, while 81% use it to treat other diseases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.
Drug repositioning is a highly studied alternative strategy to discover and develop anticancer drugs. This drug development approach identifies new indications for existing compounds. Ivermectin belongs to the group of avermectins (AVM), a series of 16-membered macrocyclic lactone compounds discovered in 1967, and FDA-approved for human use in 1987. It has been used by millions of people around the world exhibiting a wide margin of clinical safety. In this review, we summarize the in vitro and in vivo evidences demonstrating that ivermectin exerts antitumor effects in different types of cancer. Ivermectin interacts with several targets including the multidrug resistance protein (MDR), the Akt/mTOR and WNT-TCF pathways, the purinergic receptors, PAK-1 protein, certain cancer-related epigenetic deregulators such as SIN3A and SIN3B, RNA helicase, chloride channel receptors and preferentially target cancer stem-cell like population. Importantly, the in vitro and in vivo antitumor activities of ivermectin are achieved at concentrations that can be clinically reachable based on the human pharmacokinetic studies done in healthy and parasited patients. Thus, existing information on ivermectin could allow its rapid move into clinical trials for cancer patients.
https://www.tandfonline.com/doi/full/10.2147/DDDT.S237393
Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin
Ivermectin causes cell death in cancer cell lines by inducing PAK1-mediated cytostatic autophagy, caspase-dependent apoptosis and immunogenic cell death (ICD) through the modulation of some pathways, including the WNT-T cell factor (TCF), Hippo and Akt/mTOR pathways. Ivermectin can affect the growth and proliferation of cancer cells and plays several different roles, such as its functions as an RNA helicase, a small-molecule mimetic of the surface-induced dissociation (SID) peptide, an activator of chloride channel receptors, and an inducer of mitochondrial dysfunction and oxidative stress. In addition, ivermectin induces the multidrug resistance protein (MDR), has potent anti-mitotic activity, targets angiogenesis and inhibits cancer stem-like cells (CSCs). Many studies have proven that ivermectin exerts antitumour effects and might thus benefit patients with cancer after sufficient clinical trials.
https://link.springer.com/article/10.1007/s00280-020-04041-z
Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug
Ivermectin is an antiparasitic drug that exhibits antitumor effects in preclinical studies, and as such is currently being repositioned for cancer treatment. However, divergences exist regarding its employed doses in preclinical works. Therefore, the aim of this study was to determine whether the antitumor effects of ivermectin are observable at clinically feasible drug concentrations.
https://www.spandidos-publications.com/10.3892/mmr.2017.8231?text=fulltext
Ivermectin as an inhibitor of cancer stem‑like cells
The aim of the present study was to demonstrate that ivermectin preferentially inhibited cancer stem‑like cells (CSC) in breast cancer cells and downregulated the expression of ‘stemness’ genes.
https://www.sciencedirect.com/science/article/abs/pii/S0960894X19302781
Doxycycline, salinomycin, monensin and ivermectin repositioned as cancer drugs
Chemotherapy is one of the standard methods for the treatment of malignant tumors. It aims to cause lethal damage to cellular structures, mainly DNA. Noteworthy, in recent years discoveries of novel anticancer agents from well-known antibiotics have opened up new treatment pathways for several cancer diseases. The aim of this review article is to describe new applications for the following antibiotics: doxycycline (DOX), salinomycin (SAL), monensin (MON) and ivermectin (IVR) as they are known to show anti-tumor activity, but have not yet been introduced into standard oncological therapy. To date, these agents have been used for the treatment of a broad-spectrum of bacterial and parasitic infectious diseases and are widely available, which is why they were selected. The data presented here clearly show that the antibiotics mentioned above should be recognised in the near future as novel agents able to eradicate cancer cells and cancer stem cells (CSCs) across several cancer types.
https://www.nature.com/articles/s41523-021-00229-5
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
We show that treatment with the FDA-approved anti-parasitic drug ivermectin induces immunogenic cancer cell death (ICD) and robust T cell infiltration into breast tumors. As an allosteric modulator of the ATP/P2X4/P2X7 axis which operates in both cancer and immune cells, ivermectin also selectively targets immunosuppressive populations including myeloid cells and Tregs, resulting in enhanced Teff/Tregs ratio. While neither agent alone showed efficacy in vivo, combination therapy with ivermectin and checkpoint inhibitor anti-PD1 antibody achieved synergy in limiting tumor growth (p = 0.03) and promoted complete responses (p < 0.01), also leading to immunity against contralateral re-challenge with demonstrated anti-tumor immune responses. Going beyond primary tumors, this combination achieved significant reduction in relapse after neoadjuvant (p = 0.03) and adjuvant treatment (p < 0.001), and potential cures in metastatic disease (p < 0.001). Statistical modeling confirmed bona fide synergistic activity in both the adjuvant (p = 0.007) and metastatic settings (p < 0.001). Ivermectin has dual immunomodulatory and ICD-inducing effects in breast cancer, converting cold tumors hot, thus represents a rational mechanistic partner with checkpoint blockade.
https://link.springer.com/article/10.1186/s13046-019-1251-7
Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway
Our results indicated that ivermectin at its very low dose, which did not induce obvious cytotoxicity, drastically reversed the resistance of the tumor cells to the chemotherapeutic drugs both in vitro and in vivo. Mechanistically, ivermectin reversed the resistance mainly by reducing the expression of P-glycoprotein (P-gp) via inhibiting the epidermal growth factor receptor (EGFR), not by directly inhibiting P-gp activity. Ivermectin bound with the extracellular domain of EGFR, which inhibited the activation of EGFR and its downstream signaling cascade ERK/Akt/NF-κB. The inhibition of the transcriptional factor NF-κB led to the reduced P-gp transcription.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.625991/full
Computational Drug Repositioning and Experimental Validation of Ivermectin in Treatment of Gastric Cancer
Results: GC gene expression “signature” and data/pathway mining but not cMAP revealed nine molecular targets of ivermectin in both human and mouse GC associated with WNT/β-catenin signaling as well as cell proliferation pathways. In silico inhibition of the targets of ivermectin and concomitant activation of ivermectin led to the inhibition of WNT/β-catenin signaling pathway in “dose-depended” manner. In vitro, ivermectin inhibited cell proliferation in time- and concentration-depended manners, and cells were arrested in the G1 phase at IC50 and shifted to S phase arrest at >IC50. In vivo, ivermectin reduced the tumor size which was associated with inactivation of WNT/β-catenin signaling and cell proliferation pathways and activation of cell death signaling pathways.
https://www.mdpi.com/2079-9721/11/1/49
Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells
We have previously shown that pitavastatin has the potential to be used to treat ovarian cancer, although relatively high doses are likely to be necessary. One solution to this problem is to identify drugs that are synergistic with pitavastatin, thereby reducing the dose that is necessary to have a therapeutic effect. Here, we tested combinations of pitavastatin with the anti-parasitic drug ivermectin in six ovarian cancer cell lines. When tested on its own, ivermectin inhibited the growth of the cells but only with modest potency (IC50 = 10–20 µM). When the drugs were combined and assessed in cell growth assays, ivermectin showed synergy with pitavastatin in 3 cell lines and this was most evident in COV-318 cells (combination index ~ 0.6). Ivermectin potentiated the reduction in COV-318 cell viability caused by pitavastatin by 20–25% as well as potentiating apoptosis induced by pitavastatin, assessed by activation of caspase-3/7 (2–4 fold) and annexin-labelling (3–5 fold). These data suggest that ivermectin may be useful in the treatment of ovarian cancer when combined with pitavastatin, but methods to achieve an adequate ivermectin concentration in tumour tissue will be necessary.
is there a best dosage of ivermectin by cancer type?
https://www.sciencedirect.com/science/article/pii/S1043661820315152
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
out of china–there are scammy articles coming out of there sometime…SO CHECK THE REFERENCES AT THE BOTTOM OF THE ARTICLE FOR THE ACTUAL STUDIES
Ivermectin effectively suppresses the proliferation and metastasis of cancer cells and promotes cancer cell death at doses that are nontoxic to normal cells.
Ivermectin shows excellent efficacy against conventional chemotherapy drug-resistant cancer cells and reverses multidrug resistance.
Ivermectin combined with other chemotherapy drugs or targeted drugs has powerful effects on cancer.
https://timtruth.substack.com/
“CLASTOGENIC” – 18 Studies Highlighting Ivermectin Induced DNA Breakage, Damage & Related Disorders
Faith Over Fear – 11.21.23 – TURBO CANCER: Innovative Treatments Your Doctor Doesn’t Tell You. Part II: Mebendazole, Albendazole & Fenbendazole